Purpuric Papules – Friday Pop Quiz 8/11/2023
A 47-year-old patient with psoriasis, chronic venous insufficiency and venous ulcers presents with one week's history of purpuric papules with some vesiculobullous lesions affecting the lower extremities and distal forearms. The distal lesions have central necrosis with scattered erosions. The patient says the lesions itch and complains of mild abdominal pain. How should the patient be managed …
A 47-year-old patient with psoriasis, chronic venous insufficiency and venous ulcers presents with one week's history of purpuric papules with some vesiculobullous lesions affecting the lower extremities and distal forearms. The distal lesions have central necrosis with scattered erosions. The patient says the lesions itch and complains of mild abdominal pain. How should the patient be managed … Continue reading "Purpuric Papules – Friday Pop Quiz 8/11/2023"
With a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk:
Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com … 
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Amy McMichael, professor and chair of the department of dermatology at Wake Forest University School of Medicine, about her approach to recognizing, diagnosing and treating psoriasis in diverse skin tones. Watch as Dr. McMichael shares why psoriasis workups in patients with skin of color should be different. Don’t pro … 
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l … 
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o …